Table 3. Clinical trials of influenza H7N9 vaccines until July 2014.

Clinical Trial No.	Brief Title	Sponsor	Vaccine Type
1. NCT02151344	Evaluating the safety and immune response to a live H7N9 influenza virus vaccine followed by an inactivated H7N9 influenza virus vaccine, given at varying intervals	NIAID a	Egg-derived live attenuated A/Anhui/13 ca virus (H7N9) virus vaccine
2. NCT01995695
3. NCT02274545
4. NCT01938742	H7N9 mix and match with AS03 and MF59 in healthy adults	NIAID	Egg-derived A/Shanghai/2/2013 (H7N9) split vaccine
5. NCT01942265
6. NCT02251288
7. NCT02213354
8. NCT02206464	Recombinant H7 DNA plasmid Vaccine, VRC-FLUDNA071-00-VP, administered alone or with monovalent influenza subunit virion H7N9vaccine (MIV)	NIAID	Recombinant H7 DNA plasmid vaccine
9. NCT01999842	Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ influenza vaccines GSK3206641A, GSK3206640A, GSK3277510A and GSK3277509A in adults 18 to 60 years of age	GSK	Inactivated A/Shanghai/2/2013 (H7N9) vaccine
10. NCT02177734
11. NCT01897701	A/H7N9 Virus-Like Particle (VLP) antigen dose-ranging study with Adjuvant 1 or Matrix-M1 adjuvant	Novavax	Monovalent A/Anhui/1/13 (H7N9) VLP
12. NCT02078674
13. NCT01928472	Dose-finding study of four dosage levels of an H7N9 influenza vaccine in adults between ages of 18 Years and 65 Years	Novartis Vaccines	Cell-derived (MDCK) inactivated monovalent subunit H7N9 virus vaccine

^aNIAID: National Institute of Allergy and Infectious Diseases